Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer

Simple item page
dc.contributor.authorBulumulle, Anushi
dc.contributor.authorBrody, Heather
dc.contributor.authorMacherla, Shravanti
dc.contributor.authorWalker, Paul R.
dc.contributor.authorSehgal, Kartik
dc.contributor.authorGill, Ritu R.
dc.contributor.authorQilleri, Aleksandra
dc.contributor.authorMcDonald, Danielle C.
dc.contributor.authorCherry, Cynthia R.
dc.contributor.authorShea, Meghan
dc.contributor.authorHuberman, Mark S.
dc.contributor.authorVanderLaan, Paul A.
dc.contributor.authorWeiss, Glen J.
dc.contributor.authorCosta, Daniel B.
dc.contributor.authorRangachari, Deepa
dc.date.accessioned2022-09-26T18:01:38Z
dc.date.available2022-09-26T18:01:38Z
dc.date.issued2021
dc.identifier.doi10.1016/j.cllc.2020.05.028
dc.identifier.issn1525-7304
dc.identifier.urihttp://hdl.handle.net/10342/11327
dc.language.isoen_USen_US
dc.subjectExtended-interval dosingen_US
dc.subjectImmune-related adverse eventen_US
dc.subjectPatient-physician preferenceen_US
dc.titleAssociation of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Canceren_US
dc.typeArticleen_US
ecu.journal.issue3en_US
ecu.journal.nameClinical Lung Canceren_US
ecu.journal.pagese379-e389en_US
ecu.journal.volume22en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
BulumulleAssociationofExtendedDosingIntervalsorDelaysinPembrolizumabbasedRegimens.pdf
Size:
884.2 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Internal Medicine